VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

Aggregate, published by WILEY, is a premier open-access journal established in 2020, dedicated to advancing the fields of Chemistry, Materials Chemistry, Materials Science, and Molecular Biology. Based in the United States, this rapidly rising journal (Q1 in various categories as of 2023) has quickly made its mark as a valuable resource, evidenced by its impressive Scopus rankings—ranking #6 in Chemistry (miscellaneous) and #13 in Materials Science (miscellaneous) among others—place it firmly in the top percentiles of these disciplines. With an emphasis on rigorous peer-reviewed research, Aggregate provides an essential platform for researchers to disseminate groundbreaking findings and innovative methodologies that propel the scientific community forward. As an open-access journal, it ensures that cutting-edge research is accessible to a global audience, thereby enriching the dialogue among professionals, researchers, and students alike. Explore the latest advancements and contribute to the vibrant discourse in these critical areas of science by publishing with Aggregate.

RSC Chemical Biology is a prestigious journal published by the Royal Society of Chemistry, providing a significant platform for researchers in the fields of biochemistry, genetics, and molecular biology. Launched in 2020, the journal aims to disseminate high-quality research that bridges the gap between chemistry and biology, promoting interdisciplinary studies and innovations that are essential for advancements in life sciences. With an emerging impact factor and ranking in the top quartile (Q1) for multiple categories such as Biochemistry and Molecular Biology, RSC Chemical Biology holds a prominent position in the academic landscape, evidenced by its Scopus rankings placing it in the top 20% and 30% of its respective fields. Although it does not operate under an open-access model, the journal's commitment to accessibility is reflected in its rigorous peer-review process and its role in shaping future scientific discourse. Research published in this journal is vital for contributing to our understanding of complex biological processes and fostering innovations that can lead to real-world applications.

Materials Today Nano, published by Elsevier, is a premier academic journal dedicated to the forefront of nano-materials research, encompassing innovations and advancements in biomaterials, condensed matter physics, electronic, optical, and magnetic materials, as well as materials chemistry. With an impressive Q1 ranking across multiple categories, including biomaterials and materials chemistry, this journal serves as a essential platform for researchers, professionals, and students aiming to contribute to and stay informed on cutting-edge developments that push the boundaries of materials science. Its open access model allows for wider dissemination of high-impact findings, ensuring that the research reaches a global audience. Operating from the United Kingdom, Materials Today Nano plays a vital role in fostering interdisciplinary collaboration and advancing scientific understanding in this rapidly evolving field.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

BIOMACROMOLECULES, published by the American Chemical Society, stands as a premier journal in the fields of bioengineering, biomaterials, materials chemistry, and polymers and plastics. With a commendable impact factor that places it in the Q1 category across these disciplines, it is recognized for its influential research contributions and is ranked strongly within its scopes—16th in Polymers and Plastics and 26th in Biomaterials according to Scopus. Since its inception in 2000 and continuing through 2024, the journal has been pivotal in disseminating significant findings and technological advancements that propel the field forward. Although it does not currently have an open access option, the journal offers invaluable insights that are essential for researchers, professionals, and students engaged in the cutting-edge exploration of macromolecules and their diverse applications. With its address located at 1155 16th St, NW, Washington, DC 20036, BIOMACROMOLECULES is not just a repository of knowledge but also a vital platform for fostering collaboration and innovation within the scientific community.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Nanoscale Advances, published by the Royal Society of Chemistry, stands out as a leading open-access journal dedicated to advancing the field of nanoscience and nanotechnology since its inception in 2018. With a specialized focus on areas such as atomic and molecular physics, bioengineering, chemistry, and materials science, this journal has consistently achieved top-tier rankings across several categories, reflecting its high-impact contribution to research and innovation. Currently classified in the Q1 quartile for both Atomic and Molecular Physics and Chemistry (Miscellaneous), and Q2 for Bioengineering, its prestige is underscored by impressive Scopus rankings, including a notable 34th position in General Engineering. With its commitment to disseminating high-quality research, Nanoscale Advances serves as an invaluable resource for researchers, professionals, and students alike, fostering collaboration and scholarly exchange in the rapidly evolving landscape of nanotechnology.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.